Clinical Trials
2,362 trialsNCT05712356 2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Terminated
NCT01946477 2026-05-22
POM MM 014
Celgene
Phase 2 Completed
NCT04649359 2026-05-19
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Pfizer
Phase 2 Active not recruiting
NCT02213926 2026-05-18
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Acerta Pharma BV
Phase 2 Active not recruiting
NCT05846659 2026-05-15
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT01222286 2026-05-14
KIRMONO
Innate Pharma
Phase 2 Completed
NCT04619004 2026-05-14
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 2 Active not recruiting
NCT05085002 2026-05-14
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
Phase 2 Terminated
NCT05445843 2026-05-14
KontRASt-06
Novartis
Phase 2 Active not recruiting
NCT01009840 2026-05-13
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2 Completed
NCT01081951 2026-05-13
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
AstraZeneca
Phase 2 Active not recruiting
NCT04165096 2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05775289 2026-05-13
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT06119217 2026-05-13
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Trishula Therapeutics, Inc.
Phase 2 Completed
NCT06145048 2026-05-13
VISUALIZE
Vergent Bioscience, Inc.
Phase 2 Completed
NCT05246514 2026-05-12
DL-05
AstraZeneca
Phase 2 Active not recruiting
NCT05583552 2026-05-12
IMpress
GCP-Service International West GmbH
Phase 2 Active not recruiting
NCT00833417 2026-05-11
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT03431350 2026-05-11
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT03459846 2026-05-11
BAYOU
AstraZeneca
Phase 2 Active not recruiting
NCT00959647 2026-05-08
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT02365597 2026-05-08
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04325828 2026-05-08
YATAGARASU
Janssen Pharmaceutical K.K.
Phase 2 Active not recruiting
NCT05558696 2026-05-07
IMG-7289-CTP-203
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 2 Completed
NCT03962543 2026-05-06
ReNeu
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2 Active not recruiting
NCT04665843 2026-05-05
SKYSCRAPER-09
Hoffmann-La Roche
Phase 2 Completed
NCT05064358 2026-05-05
DREAMM 14
GlaxoSmithKline
Phase 2 Completed
NCT03563716 2026-05-04
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 2 Completed
NCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04083976 2026-05-04
RAGNAR
Janssen Research & Development, LLC
Phase 2 Completed
NCT03775486 2026-05-01
ORION
AstraZeneca
Phase 2 Active not recruiting
NCT04999969 2026-04-30
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
AstraZeneca
Phase 2 Active not recruiting
NCT05004350 2026-04-30
NAUTICALCRC
Pierre Fabre Medicament
Phase 2 Completed
NCT05156125 2026-04-30
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Oppilan Pharma Ltd
Phase 2 Terminated
NCT05613088 2026-04-30
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT03964727 2026-04-28
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting
NCT03580655 2026-04-24
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Completed
NCT04280081 2026-04-24
LIBRETTO-321
Eli Lilly and Company
Phase 2 Active not recruiting
NCT04745689 2026-04-24
TAZMAN
AstraZeneca
Phase 2 Active not recruiting
NCT05090566 2026-04-24
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
Phase 2 Terminated
NCT02316106 2026-04-23
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT03778229 2026-04-23
SAVANNAH
AstraZeneca
Phase 2 Active not recruiting
NCT03625323 2026-04-22
TACTI-002
Immutep S.A.S.
Phase 2 Completed
NCT03578367 2026-04-21
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Phase 2 Completed
NCT04523207 2026-04-21
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Janssen Research & Development, LLC
Phase 2 Completed
NCT04661150 2026-04-16
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT06502977 2026-04-15
DeLLphi-307
Amgen
Phase 2 Active not recruiting
NCT02864992 2026-04-13
VISION
EMD Serono
Phase 2 Active not recruiting
NCT04225117 2026-04-13
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT05440786 2026-04-13
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Phase 2 Active not recruiting